col2a primary antibody  (Proteintech)

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: CyA promotes chondrogenic differentiation of MSC . ( A ) Relative mRNA expression levels of ACAN and COL2A in MSC. ( B ) Alcian blue staining images of MSC cultured with CyA for 21 days. ( C ) Cell viability of MSC over 21 days. ( D ) Relative mRNA expression levels of ACAN, COL2A, and SOX9 in MSC over 21 days. ( E ) Protein expression levels of ACAN, COL2A, and SOX9 in MSC over 21 days. ( F ) Representative immunocytochemistry images of COL2A in MSC from Day 0 to Day 21. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, and ns = no statistically significant difference between groups.

Article Snippet: The COL2A primary antibody (1:1000, Cat# 28459-1-AP, Proteintech, USA) was applied, and the sections were incubated overnight at 4°C.

Techniques: Expressing, Staining, Cell Culture, Immunocytochemistry

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: Expression of ACAN, COL2A, SOX9, and MMP13 in chondrocytes . ( A ) Western blot analysis of ACAN, COL2A, SOX9, and MMP13 expression in chondrocytes. ( B ) Relative mRNA expression levels of ACAN, COL2A, SOX9, and MMP13 in chondrocytes. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). **P < 0.01, ***P < 0.001, and ns = no statistically significant difference between groups. ( C ) Alcian blue staining images of chondrocytes. ( D ) Immunofluorescence images of COL2A in chondrocytes. ( E ) Immunofluorescence images of MMP13 in chondrocytes.

Article Snippet: The COL2A primary antibody (1:1000, Cat# 28459-1-AP, Proteintech, USA) was applied, and the sections were incubated overnight at 4°C.

Techniques: Expressing, Western Blot, Staining, Immunofluorescence

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: In vivo therapeutic evaluation of hydrogel loaded with CyA-induced MSC . ( A ) Representative 3D reconstruction images of joints in different groups. ( B ) H&E staining of articular cartilage in different groups. ( C ) S&F staining of articular cartilage in different groups. ( D ) Immunohistochemical staining of COL2A in articular cartilage across different groups. ( E ) Immunofluorescence staining of Caspase-3 in articular cartilage across different groups. (F, G) Relative mRNA expression levels of ACAN and COL2A in joint tissues of different groups. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, and ns = no statistically significant difference between groups.

Article Snippet: The COL2A primary antibody (1:1000, Cat# 28459-1-AP, Proteintech, USA) was applied, and the sections were incubated overnight at 4°C.

Techniques: In Vivo, Staining, Immunohistochemical staining, Immunofluorescence, Expressing

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: CyA promotes chondrogenic differentiation of MSC . ( A ) Relative mRNA expression levels of ACAN and COL2A in MSC. ( B ) Alcian blue staining images of MSC cultured with CyA for 21 days. ( C ) Cell viability of MSC over 21 days. ( D ) Relative mRNA expression levels of ACAN, COL2A, and SOX9 in MSC over 21 days. ( E ) Protein expression levels of ACAN, COL2A, and SOX9 in MSC over 21 days. ( F ) Representative immunocytochemistry images of COL2A in MSC from Day 0 to Day 21. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, and ns = no statistically significant difference between groups.

Article Snippet: Overnight incubation at 4°C with diluted primary antibodies followed: ACAN (1:2000, Cat# 68350-1-Ig, Proteintech, USA), COL2A (1:2000, Cat# 28459-1-AP, Proteintech, USA), SOX9 (1:2000, Cat# 67439-1-Ig, Proteintech, USA), MMP13 (1:2000, Cat# 18165-1-AP, Proteintech, USA), CD9 (1:1000, Cat# 13174, CST, USA), CD63 (1:1000, Cat# 52090, CST, USA), GM130 (1:1000, Cat# 12480, CST, USA), Bcl-2 (1:1000, Cat# 3498, CST, USA), P53 (1:1000, Cat# 9282, CST, USA), and GAPDH (1:10000, Cat# 10494-1-AP, Proteintech, USA).

Techniques: Expressing, Staining, Cell Culture, Immunocytochemistry

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: Expression of ACAN, COL2A, SOX9, and MMP13 in chondrocytes . ( A ) Western blot analysis of ACAN, COL2A, SOX9, and MMP13 expression in chondrocytes. ( B ) Relative mRNA expression levels of ACAN, COL2A, SOX9, and MMP13 in chondrocytes. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). **P < 0.01, ***P < 0.001, and ns = no statistically significant difference between groups. ( C ) Alcian blue staining images of chondrocytes. ( D ) Immunofluorescence images of COL2A in chondrocytes. ( E ) Immunofluorescence images of MMP13 in chondrocytes.

Article Snippet: Overnight incubation at 4°C with diluted primary antibodies followed: ACAN (1:2000, Cat# 68350-1-Ig, Proteintech, USA), COL2A (1:2000, Cat# 28459-1-AP, Proteintech, USA), SOX9 (1:2000, Cat# 67439-1-Ig, Proteintech, USA), MMP13 (1:2000, Cat# 18165-1-AP, Proteintech, USA), CD9 (1:1000, Cat# 13174, CST, USA), CD63 (1:1000, Cat# 52090, CST, USA), GM130 (1:1000, Cat# 12480, CST, USA), Bcl-2 (1:1000, Cat# 3498, CST, USA), P53 (1:1000, Cat# 9282, CST, USA), and GAPDH (1:10000, Cat# 10494-1-AP, Proteintech, USA).

Techniques: Expressing, Western Blot, Staining, Immunofluorescence

Journal: Aging and Disease

Article Title: Enhanced Chondrogenic Potential and Osteoarthritis Treatment Using Cyaonoside A-Induced MSC Delivered via a Hyaluronic Acid-Based Hydrogel System

doi: 10.14336/AD.2024.10016

Figure Lengend Snippet: In vivo therapeutic evaluation of hydrogel loaded with CyA-induced MSC . ( A ) Representative 3D reconstruction images of joints in different groups. ( B ) H&E staining of articular cartilage in different groups. ( C ) S&F staining of articular cartilage in different groups. ( D ) Immunohistochemical staining of COL2A in articular cartilage across different groups. ( E ) Immunofluorescence staining of Caspase-3 in articular cartilage across different groups. (F, G) Relative mRNA expression levels of ACAN and COL2A in joint tissues of different groups. Statistical significance was determined using one-way ANOVA for multiple group comparisons, followed by post hoc tests. All data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, and ns = no statistically significant difference between groups.

Article Snippet: Overnight incubation at 4°C with diluted primary antibodies followed: ACAN (1:2000, Cat# 68350-1-Ig, Proteintech, USA), COL2A (1:2000, Cat# 28459-1-AP, Proteintech, USA), SOX9 (1:2000, Cat# 67439-1-Ig, Proteintech, USA), MMP13 (1:2000, Cat# 18165-1-AP, Proteintech, USA), CD9 (1:1000, Cat# 13174, CST, USA), CD63 (1:1000, Cat# 52090, CST, USA), GM130 (1:1000, Cat# 12480, CST, USA), Bcl-2 (1:1000, Cat# 3498, CST, USA), P53 (1:1000, Cat# 9282, CST, USA), and GAPDH (1:10000, Cat# 10494-1-AP, Proteintech, USA).

Techniques: In Vivo, Staining, Immunohistochemical staining, Immunofluorescence, Expressing